Highlights • Patients who received no AST had a 2.5% lower 8-year DMFI rate than observed in matched patients who received ET. • Slightly more locoregional recurrences and contralateral breast cancers were observed in patients who received no AST. • These effects and side effects of ET should be discussed with patients even at a very low risk of distant metastasis. ABSTRACT Background Adjuvant systemic treatments (AST) reduce mortality, but have associated short- and long-term toxicities.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with D.
Contact D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack